Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/DNTH · Entity 1813 | EVP, CFO & CBO | July 09, 2026 | July 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dianthus Therapeutics, Inc. /DE/
Report date July 09, 2026 · Filed July 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-07-09 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-07-09 · Exercise / conversion · Acquired 31,249 · Balance 31,249 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. Row 2 · 2026-07-09 · Sale · Disposed 10,354 · Balance 20,895 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $99.75 to $100.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Row 3 · 2026-07-09 · Sale · Disposed 15,329 · Balance 5,566 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. F3: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $100.78 to $101.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Row 4 · 2026-07-09 · Sale · Disposed 5,566 · Balance 0 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. F4: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $101.95 to $102.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.77 · Expires 2034-05-22 | Direct | 68,751 |
Reported balance
After 2026-07-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-09 · Exercise / conversion · Disposed 31,249 · Balance 68,751 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. F5: The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025.
F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $99.75 to $100.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $100.78 to $101.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F4: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $101.95 to $102.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F5: The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2026 Filed Jul 13, 2026 21:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 31,249 | $0.00 Strike: $21.77 | $0.00 |
DisclosureSEC source: 0001992324-26-000008 · ownership.xml · derivative · entry 5 Savitz Ryan · CIK 0001992324 · EVP, CFO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,751 Underlying: Common Stock · 31,249 shares Expires 2034-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. F5 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 21:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 5,566 | $101.97 | $567,565.02 |
DisclosureSEC source: 0001992324-26-000008 · ownership.xml · nonDerivative · entry 4 Savitz Ryan · CIK 0001992324 · EVP, CFO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $101.95 to $102.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 21:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 15,329 | $101.24 | $1,551,907.96 |
DisclosureSEC source: 0001992324-26-000008 · ownership.xml · nonDerivative · entry 3 Savitz Ryan · CIK 0001992324 · EVP, CFO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,566 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $100.78 to $101.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 21:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 10,354 | $100.22 | $1,037,677.88 |
DisclosureSEC source: 0001992324-26-000008 · ownership.xml · nonDerivative · entry 2 Savitz Ryan · CIK 0001992324 · EVP, CFO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,895 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $99.75 to $100.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 21:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 31,249 | $21.77 | $680,290.73 |
DisclosureSEC source: 0001992324-26-000008 · ownership.xml · nonDerivative · entry 1 Savitz Ryan · CIK 0001992324 · EVP, CFO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,249 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. Read SEC document |
| April 09, 2026 Filed Apr 10, 2026 20:52 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,224 | $0.00 Strike: $17.88 | $0.00 |
DisclosureSEC source: 0001992324-26-000006 · ownership.xml · derivative · entry 3 Savitz Ryan · CIK 0001992324 · EVP, CFO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,776 Underlying: Common Stock · 8,224 shares Expires 2034-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. F3 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| April 09, 2026 Filed Apr 10, 2026 20:52 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 8,224 | $89.84 | $738,844.16 |
DisclosureSEC source: 0001992324-26-000006 · ownership.xml · nonDerivative · entry 2 Savitz Ryan · CIK 0001992324 · EVP, CFO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.75 to $89.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 09, 2026 Filed Apr 10, 2026 20:52 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 8,224 | $17.88 | $147,045.12 |
DisclosureSEC source: 0001992324-26-000006 · ownership.xml · nonDerivative · entry 1 Savitz Ryan · CIK 0001992324 · EVP, CFO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 21:26 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $17.88 | $0.00 |
DisclosureSEC source: 0001992324-26-000004 · ownership.xml · derivative · entry 12 Savitz Ryan · CIK 0001992324 · EVP, CFO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 40,000 shares Expires 2034-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. F11 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 21:26 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 74,367 | $0.00 Strike: $8.44 | $0.00 |
DisclosureSEC source: 0001992324-26-000004 · ownership.xml · derivative · entry 11 Savitz Ryan · CIK 0001992324 · EVP, CFO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,399 Underlying: Common Stock · 74,367 shares Expires 2032-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. F10 · derivative.exercise_date: The shares of common stock underlying this stock option award vested as to 25% of the shares on June 2, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 21:26 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 7,232 | $85.54 | $618,625.28 |
DisclosureSEC source: 0001992324-26-000004 · ownership.xml · nonDerivative · entry 10 Savitz Ryan · CIK 0001992324 · EVP, CFO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. F9 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.25 to $85.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 21:26 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 19,469 | $84.57 | $1,646,493.33 |
DisclosureSEC source: 0001992324-26-000004 · ownership.xml · nonDerivative · entry 9 Savitz Ryan · CIK 0001992324 · EVP, CFO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,232 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. F8 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $84.25 to $85.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 21:26 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 59,800 | $83.90 | $5,017,220.00 |
DisclosureSEC source: 0001992324-26-000004 · ownership.xml · nonDerivative · entry 8 Savitz Ryan · CIK 0001992324 · EVP, CFO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,701 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. F7 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.25 to $84.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 21:26 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 2,366 | $82.84 | $195,999.44 |
DisclosureSEC source: 0001992324-26-000004 · ownership.xml · nonDerivative · entry 7 Savitz Ryan · CIK 0001992324 · EVP, CFO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,501 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. F6 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.25 to $83.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 21:26 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 800 | $81.36 | $65,088.00 |
DisclosureSEC source: 0001992324-26-000004 · ownership.xml · nonDerivative · entry 6 Savitz Ryan · CIK 0001992324 · EVP, CFO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,867 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. F5 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.15 to $81.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 21:26 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 1,485 | $80.25 | $119,171.25 |
DisclosureSEC source: 0001992324-26-000004 · ownership.xml · nonDerivative · entry 5 Savitz Ryan · CIK 0001992324 · EVP, CFO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,667 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.11 to $81.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 21:26 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 21,825 | $78.86 | $1,721,119.50 |
DisclosureSEC source: 0001992324-26-000004 · ownership.xml · nonDerivative · entry 4 Savitz Ryan · CIK 0001992324 · EVP, CFO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,152 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $78.74 to $79.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 21:26 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 1,390 | $78.33 | $108,878.70 |
DisclosureSEC source: 0001992324-26-000004 · ownership.xml · nonDerivative · entry 3 Savitz Ryan · CIK 0001992324 · EVP, CFO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,977 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $77.74 to $78.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 21:26 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 40,000 | $17.88 | $715,200.00 |
DisclosureSEC source: 0001992324-26-000004 · ownership.xml · nonDerivative · entry 2 Savitz Ryan · CIK 0001992324 · EVP, CFO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,367 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 21:26 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 74,367 | $8.44 | $627,657.48 |
DisclosureSEC source: 0001992324-26-000004 · ownership.xml · nonDerivative · entry 1 Savitz Ryan · CIK 0001992324 · EVP, CFO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,367 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. Read SEC document |
| February 03, 2026 Filed Feb 4, 2026 22:40 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $52.46 | $0.00 |
DisclosureSEC source: 0001992324-26-000002 · ownership.xml · derivative · entry 1 Savitz Ryan · CIK 0001992324 · EVP, CFO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2036-02-03 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after January 1, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| December 04, 2025 Filed Dec 6, 2025 01:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $8.44 | $0.00 |
DisclosureSEC source: 0001992324-25-000005 · ownership.xml · derivative · entry 3 Savitz Ryan · CIK 0001992324 · CFO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,766 Underlying: Common Stock · 20,000 shares Expires 2032-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2025. F3 · derivative.exercise_date: The shares of common stock underlying this stock option award vested as to 25% of the shares on June 2, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| December 04, 2025 Filed Dec 6, 2025 01:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 20,000 | $45.18 | $903,600.00 |
DisclosureSEC source: 0001992324-25-000005 · ownership.xml · nonDerivative · entry 2 Savitz Ryan · CIK 0001992324 · CFO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 04, 2025 Filed Dec 6, 2025 01:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 20,000 | $8.44 | $168,800.00 |
DisclosureSEC source: 0001992324-25-000005 · ownership.xml · nonDerivative · entry 1 Savitz Ryan · CIK 0001992324 · CFO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2025. Read SEC document |
| September 23, 2025 Filed Sep 26, 2025 00:02 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $37.87 | $0.00 |
DisclosureSEC source: 0001992324-25-000003 · ownership.xml · derivative · entry 1 Savitz Ryan · CIK 0001992324 · CFO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2035-09-23 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after September 23, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 21:20 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $8.44 | $0.00 |
DisclosureSEC source: 0000950170-25-114293 · ownership.xml · derivative · entry 3 Savitz Ryan · CIK 0001992324 · CFO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,766 Underlying: Common Stock · 20,000 shares Expires 2032-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2025. F2 · derivative.exercise_date: The shares of common stock underlying this stock option award vested as to 25% of the shares on June 2, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 21:20 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 20,000 | $35.00 | $700,000.00 |
DisclosureSEC source: 0000950170-25-114293 · ownership.xml · nonDerivative · entry 2 Savitz Ryan · CIK 0001992324 · CFO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2025. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 21:20 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 20,000 | $8.44 | $168,800.00 |
DisclosureSEC source: 0000950170-25-114293 · ownership.xml · nonDerivative · entry 1 Savitz Ryan · CIK 0001992324 · CFO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2025. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 21:18 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $22.07 | $0.00 |
DisclosureSEC source: 0000950170-25-013471 · ownership.xml · derivative · entry 1 Savitz Ryan · CIK 0001992324 · CFO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2035-02-02 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after January 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| May 23, 2024 Filed May 29, 2024 00:04 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $21.77 | $0.00 |
DisclosureSEC source: 0000950170-24-065564 · ownership.xml · derivative · entry 1 Savitz Ryan · CIK 0001992324 · CFO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-05-22 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 21:41 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $17.88 | $0.00 |
DisclosureSEC source: 0000950170-24-007986 · ownership.xml · derivative · entry 1 Savitz Ryan · CIK 0001992324 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2034-01-23 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.